A stage I clinical trial of Cemiplimab-rwlc, radiotherapy, cyclophosphamide, and GM-CSF in patients with R/M HNSCC (NCT02383212) revealed that the impact of Cemiplimab-rwlc in conjunction with radiotherapy, cyclophosphamide, and GM-CSF might be similar to anti-PD‐1 monotherapy [81]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.